-transparent.png){kind=logo}
Fifty normal control volunteers were patch tested to 20% neomycin as well as tobramycin 1%, 10%, 20% and 30% in white petrolatum. Tobramycin is a new aminoglycoside antibiotic for prescription ophthalmologic use in the United States. There were no reactions on any of the control volunteers. Twenty known and proven neomycin-allergic patients were then tested to tobramycin 10% and 20% in white petrolatum, as well as to neomycin 20% aqueous and 20% in white petrolatum. All 20 reacted with a 2+ or greater response to the neomycin patch tests. Twelve out of the 20 or 60% of the neomycin-allergic patients reacted to the 10% tobramycin in white petrolatum. Thirteen out of 20 or 65% reacted to 20% tobramycin in white petrolatum. From these data, tobramycin (ophthalmic) should not be used to treat known neomycin-allergic patients without first patch testing the patient with 20% tobramycin in white petrolatum. It appears probable that 65% of neomycin-allergic patients would react with a dermatitic response to such therapy.
W F Schorr, and
H B Ridgway
January 2016,
Dermatitis : contact, atopic, occupational, drug,
W F Schorr, and
H B Ridgway
January 1979,
Acta dermato-venereologica. Supplementum,
W F Schorr, and
H B Ridgway
October 1978,
Contact dermatitis,
W F Schorr, and
H B Ridgway
December 1980,
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
W F Schorr, and
H B Ridgway
January 1972,
Nihon Ika Daigaku zasshi,
W F Schorr, and
H B Ridgway
September 1998,
Contact dermatitis,
W F Schorr, and
H B Ridgway
January 1968,
Dermatologica,
W F Schorr, and
H B Ridgway
March 1961,
Canadian Medical Association journal,
